ストックスクリーナーアプリを入手
5.76
0.69%
-0.04
アフターアワーズ：
5.83
0.07
+1.22%
Design Therapeutics Inc (DSGN) 最新ニュース
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - The Manila Times
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Design Therapeutics (DSGN) to Present at Two Major Healthcare Conferences | DSGN Stock News - StockTitan
Design Therapeutics stock soars to 52-week high of $6.91 By Investing.com - Investing.com Canada
Design Therapeutics stock soars to 52-week high of $6.91 - Investing.com India
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies - Nature.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Design Therapeutics Reports Strong Q3 and Pipeline Progress - TipRanks
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - Marketscreener.com
Design Therapeutics Reports $254M Cash Runway, Advances Clinical Pipeline Through 2029 | DSGN Stock News - StockTitan
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Yahoo Finance
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, - GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI - Yahoo Finance
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Longview News-Journal
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Dr. Beyza Bulutoglu Celebrated for Dedication to the Field of Protein Engineering and Drug Discovery - 24-7 Press Release
Spinocerebellar Ataxias Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News
Nitric Oxide-Photodelivering Materials with Multiple Functionalities: From Rational Design to Therapeutic Applications - ACS Publications
Synthetic Nanoassemblies for Regulating Organelles: From Molecular Design to Precision Therapeutics - ACS Publications
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models - ACS Publications
When (DSGN) Moves Investors should Listen - Stock Traders Daily
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index - Yahoo Finance
OSE Immunotherapeutics Presents New “Cis-Demasking” - GlobeNewswire
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential - ForexTV.com
Glycomic Therapeutics Market Innovations, Challenges, - openPR
Dimensional Fund Advisors LP Has $271,000 Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Reduces Holdings in TrueCar, Inc. (NASDAQ:TRUE) - Defense World
Squarepoint Ops LLC Has $294,000 Stock Holdings in Civeo Co. (NYSE:CVEO) - Defense World
Squarepoint Ops LLC Increases Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Squarepoint Ops LLC Lowers Stock Holdings in AerSale Co. (NASDAQ:ASLE) - Defense World
Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder - BioSpace
Tech News | American Press Technology News - Business Wire
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MyChesCo
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - Yahoo Finance
Cubist Systematic Strategies LLC Grows Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Relay Therapeutics to Lay Off 10% of Workforce - BioSpace
Point72 Asset Management L.P. Buys 397,285 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Point72 Asset Management L.P. Has $3.32 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Point72 Asset Management L.P. Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Almitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Almitas Capital LLC Purchases 227,180 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Wall Street SWOT: Design Therapeutics stockInnovative approach in genetic disorder treatment - Investing.com
(DSGN) On The My Stocks Page - Stock Traders Daily
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock - Yahoo Finance
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire
Halozyme Therapeutics And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - StockTitan
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight - Barchart
Initial in vivo validation of novel cancer therapeutics using AI - Drug Target Review
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):